{
    "clinical_study": {
        "@rank": "48770", 
        "arm_group": [
            {
                "arm_group_label": "Group 1 Hib-CRM197", 
                "arm_group_type": "Active Comparator", 
                "description": "Vaccine Groups in V37_07E1 study"
            }, 
            {
                "arm_group_label": "Group 2: Hib-TT", 
                "arm_group_type": "Active Comparator", 
                "description": "Vaccine Groups in V37_07E1 study"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the persistency of immune response against Haemophilus influenzae type b by\n      assessing anti-PRP antibody levels in children vaccinated with either Hib-CRM197 or Hib-TT\n      booster vaccine approximately 4 years before."
        }, 
        "brief_title": "Persistency Study After Hib-CRM197 or Hib-TT Vaccines in Chinese Children", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Haemophilus Influenzae Type b Invasive Disease", 
            "Gram-negative Invasive Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Haemophilus Infections", 
                "Influenza, Human"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. children previously enrolled in V37_07E1 study and who received the appropriate\n             vaccination.\n\n          2. children whose parent(s) or legal guardian(s) have given written consent after the\n             nature of the study has been explained according to local regulatory requirements.\n\n        Exclusion Criteria:\n\n          1. any confirmed or suspected current immunosuppressive or immunodeficient condition\n             since the end of V37_07E1 study, based on medical history and physical examination\n             (no laboratory testing required).\n\n          2. treatment with corticosteroids or other immunosuppressive/immunostimulant drugs as\n             defined below: i) chronic use of oral and parenteral immunosuppressants (>/= 15 days\n             of use) or other immune-modifying drugs within 60 days prior to the blood sampling\n             (short term usage of topic, inhaled and/or intranasal corticosteroids is allowed) ii)\n             receipt of immunostimulants within 60 days prior to Visit 1\n\n          3. administration of immunoglobulines and/or any blood products up to 3 months before\n             enrollment.\n\n          4. use of any investigational or non-registered product (drug or vaccine) within 30 days\n             preceding the blood sampling.\n\n          5. any condition, which, in the opinion of the investigator, might be a contraindication\n             to the execution of the blood draw."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "6 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "660", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139228", 
            "org_study_id": "V37_07E2"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1 Hib-CRM197", 
                "description": "no vaccine administered in V37_07E2 study", 
                "intervention_name": "Hib-CRM197 in V37_07E1", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group 2: Hib-TT", 
                "description": "no vaccine administered in V37_07E2 study", 
                "intervention_name": "Hib-TT in V37_07E1 study", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Haemophilus influenzae type b", 
            "persistency", 
            "children", 
            "CRM197", 
            "anti-PRP antibody"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "contact": {
                "email": "yuliang_zh@163.com", 
                "last_name": "Yuliang Zhao", 
                "phone": "+86 15931052736"
            }, 
            "facility": {
                "address": {
                    "city": "Dingxing", 
                    "country": "China", 
                    "state": "Hebei", 
                    "zip": "050021"
                }, 
                "name": "DingXing CDC"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension Study in Chinese Children After a 2 + 1 Dose Series of Either CRM197- Conjugate Haemophilus Influenzae Type b Vaccine or Tetanus Toxoid-conjugate Haemophilus Influenzae Type b Vaccine.", 
        "overall_contact": {
            "last_name": "Novartis Drug Information Services", 
            "phone": "+1 800 244 7668"
        }, 
        "overall_official": {
            "affiliation": "Novartis Vaccines", 
            "last_name": "Novartis Vaccines", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess anti- PRP antibodies persistency in children participating in previous V37_07E1 trial, approximately 4 years after booster vaccination with either Hib-CRM197 or Hib-TT.", 
            "measure": "Ratio of anti-PRP antibody geometric mean concentrations (GMCs), approximately four years after booster vaccination by vaccine group.", 
            "safety_issue": "No", 
            "time_frame": "day 1 (four years after booster vaccination received in V37_07E1 study)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139228"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}